Brain aging and Parkinson's disease: New therapeutic approaches using drug delivery systems

Maturitas

Volumn 84, Issue , 2016, Pages 25-31

  Rodriguez Nogales C ^a   Garbayo, E ^a,b   Carmona Abellan M M ^c   Luquin, M R ^b,c   Blanco Prieto, M J ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IdiSNA Navarra Institute for Health Research   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Aging; Alpha synuclein; Drug delivery systems; GDNF; Micro nanoparticles; Parkinson disease; Therapeutic targets

Indexed keywords

ALGINIC ACID; ALPHA SYNUCLEIN; ANTIOXIDANT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; LIPOSOME; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MONOAMINE OXIDASE INHIBITOR; NANOPARTICLE; NEUROPROTECTIVE AGENT; PROTEASOME; RASAGILINE; RESVERATROL; RETINOIC ACID; ROPINIROLE; UBIQUITIN PROTEIN LIGASE E3; VASCULOTROPIN; NERVE GROWTH FACTOR; PEPTIDE;

ACTIVE IMMUNIZATION; AGING; AUTOOXIDATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DRUG DELIVERY SYSTEM; GLIA; HUMAN; HYDROGEL; LYSOSOME; META ANALYSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; STEREOTAXIC SURGERY; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TRANSDERMAL PATCH; UBIQUITINATION; VIRAL GENE DELIVERY SYSTEM; BRAIN; GENE THERAPY; LEWY BODY; METABOLISM; MITOCHONDRION; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGING; ALPHA-SYNUCLEIN; ANTIOXIDANTS; BRAIN; DOPAMINE; DOPAMINE AGONISTS; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; LEWY BODIES; LYSOSOMES; MITOCHONDRIA; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84952638039     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2015.11.009     Document Type: Review

References (56)

1. L.V. Kalia, and A.E. Lang Parkinson's disease Lancet 6736 2015 1 17
2. V.E. Mosharov, K.E. Larsen, E. Kanter, K.A. Phillips, K. Wilson, Y. Schmitz, and et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons Neuron 62 2009 218 229
3. T.A. Yacoubian, and D.G. Standaert Targets for neuroprotection in Parkinson's disease Biochim. Biophys. Acta 1792 2009 676 687
4. B. Dehay, M. Bourdenx, P. Gorry, S. Przedborski, M. Vila, S. Hunot, and et al. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations Lancet Neurol. 2015 855 866
5. M.G. Spillantini, M.L. Schmidt, V.M.-Y. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert [alpha]-Synuclein in Lewy bodies Nature. 388 1997 839 840
6. S.K. Van Den Eeden, C.M. Tanner, A.L. Bernstein, R.D. Fross, A. Leimpeter, D.a Bloch, and et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity Am. J. Epidemiol. 157 2003 1015 1022
7. A. Beilina, and M.R. Cookson Genes associated with Parkinson's disease: regulation of autophagy and beyond J. Neurochem. 2015
8. T. Collier, N. Kanaan, and J. Kordower Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates Nat. Rev. Neurosci. 12 2011 359 366
9. M. Rodriguez, I. Morales, C. Rodriguez-Sabate, A. Sanchez, R. Castro, J.M. Brito, and et al. The degeneration and replacement of dopamine cells in Parkinson’S disease: the role of aging Front. Neuroanat. 8 2014 1 7
10. M.D. Yahr, R.C. Duvoisin, M.J. Schear, R.E. Barrett, and M.M. Hoehn Treatment of parkinsonism with levodopa Arch. Neurol. 21 1969 343 354
11. G.C. Cotzias Levodopa in the treatment of Parkinsonism JAMA 218 1971 1903 1908
12. W. Maetzler, I. Liepelt, and D. Berg Progression of Parkinson's disease in the clinical phase: potential markers Lancet Neurol. 8 2009 1158 1171
13. A. Todorova, P. Jenner, and K. Ray Chaudhuri Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected Pract. Neurol. 2014 1 13
14. K. Seppi, D. Weintraub, M. Coelho, S. Perez-Lloret, S.H. Fox, R. Katzenschlager, and et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease Mov. Disord. 26 Suppl. (3) 2011 S42 S80
15. E. Garbayo, E. Ansorena, and M.J. Blanco-Prieto Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems Maturitas 76 2013 272 278
16. J. Burré, M. Sharma, and T.C. Südhof α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation Proc. Natl. Acad. Sci. U. S. A. 111 2014 E4274 E4283
17. B.D. Looyenga, and P. Brundin Silencing synuclein at the synapse with PLK2 Proc. Natl. Acad. Sci. U. S. A. 110 2013 16293 16294
18. K.J. Inglis, D. Chereau, E.F. Brigham, S.S. Chiou, S. Schöbel, N.L. Frigon, and et al. Polo-like kinase 2 (PLK2) phosphorylates α-synuclein at serine 129 in central nervous system J. Biol. Chem. 284 2009 2598 2602
19. J. Li, W. Ma, P.Y. Wang, P.J. Hurley, F. Bunz, and P.M. Hwang Polo-like kinase 2 activates an antioxidant pathway to promote the survival of cells with mitochondrial dysfunction Free Radic. Biol. Med. 73 2014 270 277
20. O. Cizmecioglu, S. Warnke, M. Arnold, S. Duensing, and I. Hoffmann Plk2 regulated centriole duplication is dependent on its localization to the centrioles and a functional polo-box domain Cell Cycle 7 2008 3548 3555
21. Q. Zhang, Y.-C. Kim, and N.S. Narayanan Disease-modifying therapeutic directions for Lewy-body dementias Front. Neurosci. 9 2015 1 9
22. P. Brundin, G. Atkin, and J.T. Lamberts Basic science breaks through: new therapeutic advances in Parkinson's disease Mov. Disord. 30 2015 1521 1527
23. C. Zhou, and S. Przedborski Intrabody and Parkinson's disease Biochim. Biophys. Acta - Mol. Basis Dis. 1792 2009 634 642
24. J.M. Deger, J.E. Gerson, and R. Kayed The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration Aging Cell 14 2015 715 724
25. T. Pan, S. Kondo, W. Le, and J. Jankovic The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease Brain 131 2008 1969 1978
26. M. Xilouri, O.R. Brekk, D. Kirik, and L. Stefanis LAMP2A as a therapeutic target in Parkinson disease Autophagy 9 2013 2166 2168
27. G.K. Tofaris Lysosome-dependent pathways as a unifying theme in Parkinson's disease Mov. Disord. 27 2012 1364 1369
28. B. Dehay, M. Martinez-Vicente, G.A. Caldwell, K.A. Caldwell, Z. Yue, M.R. Cookson, and et al. Lysosomal impairment in Parkinson's disease Mov. Disord. 28 2013 725 732
29. K.E. Murphy, A.M. Gysbers, S.K. Abbott, A.S. Spiro, A. Furuta, A. Cooper, and et al. Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease Mov. Disord. 30 2015 1639 1647 10.1002/mds.26141
30. B.D. Lee, J.-H. Shin, J. VanKampen, L. Petrucelli, A.B. West, H.S. Ko, and et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease Nat. Med. 16 2010 998 1000
31. L. Hang, J. Thundyil, and K.-L. Lim Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuroprotection Ann. N. Y. Acad. Sci. 1350 2015 37 47
32. A. Bir, O. Sen, S. Anand, V.K. Khemka, P. Banerjee, R. Cappai, and et al. α-Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson's disease J. Neurochem. 131 2014 868 877
33. C.S. Chan, T.S. Gertler, and D.J. Surmeier Calcium homeostasis, selective vulnerability and Parkinson's disease Trends Neurosci. 32 2009 249 256
34. A. Umemura, T. Oeda, K. Yamamoto, S. Tomita, and M. Kohsaka Baseline Plasma c-reactive protein concentrations and motor prognosis in Parkinson disease PLoS One 41 2015 1 12
35. K.S. Kang, S.-I. Lee, J.M. Hong, J.W. Lee, H.Y. Cho, J.H. Son, and et al. Hybrid scaffold composed of hydrogel/3D-framework and its application as a dopamine delivery system J. Control. Release 175 2014 10 16
36. E. Garbayo, C.N. Montero-Menei, E. Ansorena, J.L. Lanciego, M.S. Aymerich, and M.J. Blanco-Prieto Effective GDNF brain delivery using microspheres - a promising strategy for Parkinson's disease J. Control. Release 135 2009 119 126
37. E. Garbayo, E. Ansorena, J.L. Lanciego, M.J. Blanco-Prieto, and M.S. Aymerich Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease Mov. Disord. 26 2011 1943 1947
38. E. Garbayo, H. Lana, G. DAddario, M.M. Carmona-Abellan, I. Marcilla, J.L. Lanciego, and et al. Parkinsonian monkeys showed brain structural and functional recovery following local delivery of microencapsulated GDNF Present. Annu. Meet. Control. Release Soc. Edinburgh 2015
39. E. Herrán, C. Requejo, J.A. Ruiz-Ortega, A. Aristieta, M. Igartua, H. Bengoetxea, and et al. Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease Int. J. Nanomed. 9 2014 2677 2687
40. T.C. Moloney, M. Ní Fhlathartaigh, M. Kulkarni, A. Pandit, and E. Dowd Fibrin as a scaffold for delivery of GDNF overexpressing stem cells to the adult rat brain ACS Biomater. Sci. Eng. 1 2015 559 566
41. C. Requejo, J.A. Ruiz-Ortega, H. Bengoetxea, A. Garcia-Blanco, E. Herrán, A. Aristieta, and et al. Topographical distribution of morphological changes in a partial model of Parkinson's disease-effects of nanoencapsulated neurotrophic factors administration Mol. Neurobiol. 52 2015 846 858
42. D. Singh, H. Kapahi, M. Rashid, A. Prakash, A.B.A. Majeed, and N. Mishra Recent prospective of surface engineered nanoparticles in the management of neurodegenerative disorders Artif. Cells Nanomed. Biotechnol. 2015 1 12
43. G. Leyva-Gómez, H. Cortés, J.J. Magaña, N. Leyva-García, D. Quintanar-Guerrero, and B. Florán Nanoparticle technology for treatment of Parkinson's disease: the role of surface phenomena in reaching the brain Drug Discov. Today 2015 20
44. R. Pahuja, K. Seth, A. Shukla, R.K. Shukla, and P. Bhatnagar Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats ACS Nano 9 2015 4850 4871
45. P.Y. Gambaryan, I.G. Kondrasheva, E.S. Severin, A.A. Guseva, and A.A. Kamensky Increasing the efficiency of Parkinson's disease treatment using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA delivery system Exp. Neurobiol. 23 2014 246 252
46. S. Di Gioia, A. Trapani, D. Mandracchia, E. De Giglio, S. Cometa, V. Mangini, and et al. Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-β-cyclodextrin based nanoparticles Eur. J. Pharm. Biopharm. 94 2015 180 193
47. C.-T. Lu, R. Jin, Y. Jiang, Q. Lin, W.-Z. Yu, K.-L. Mao, and et al. Gelatin nanoparticle-mediated intranasal delivery of substance P protects against 6-hydroxydopamine-induced apoptosis: an in vitro and in vivo study Drug Des. Dev. Ther. 9 2015 1955 1962
48. D. Mittal, S. Md, Q. Hasan, M. Fazil, A. Ali, S. Baboota, and et al. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route Drug Deliv. 2015 1 10
49. O. Jafarieh, S. Md, M. Ali, S. Baboota, J.K. Sahni, B. Kumari, and et al. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting Drug Dev. Ind. Pharm. 41 2014 1 8
50. Y.Y. Liu, X.Y. Yang, Z. Li, Z.L. Liu, D. Cheng, Y. Wang, and et al. Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease CNS Neurosci. Ther. 20 2014 76 85
51. R. Huang, H. Ma, Y. Guo, S. Liu, Y. Kuang, K. Shao, and et al. Angiopep-conjugated nanoparticles for targeted long-term gene therapy of parkinson's disease Pharm. Res. 30 2013 2549 2559
52. Y.S. Peng, P.L. Lai, S. Peng, H.C. Wu, S. Yu, T.Y. Tseng, and et al. Int. J. Nanomed. 9 2014 3163 3174
53. G. Da Rocha Lindner, D. Bonfanti Santos, D. Colle, E.L. Gasnhar Moreira, R. Daniel Prediger, M. Farina, and et al. Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism Nanomedicine (Lond.) 10 2015 1127 1138
54. M.J. Haney, N.L. Klyachko, Y. Zhao, R. Gupta, E.G. Plotnikova, Z. He, and et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy J. Control. Release 207 2015 18 30
55. M. Esteves, A.C. Cristóvão, T. Saraiva, S.M. Rocha, G. Baltazar, L. Ferreira, and et al. Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson's disease Front. Aging Neurosci. 7 2015 1 10
56. Y.Z. Zhao, X. Li, C.T. Lu, M. Lin, L.J. Chen, Q. Xiang, and et al. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats Nanomed. Nanotechnol. Biol. Med. 10 2014 755 764